SCHEMBL2918340

SCHEMBL2918340

CCCCCc1ccccc1NC(=S)NC(=O)c1cc2ccncc2o1

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.52
NPC1 O15118 3/20 0.47
RAB9A P51151 2/20 0.47
MAPT P10636 2/20 0.47
HTT P42858 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
HPGD P15428 1/20 0.43
MIF P14174 1/20 0.43
NAMPT P43490 4/20 0.43
CYP2C9 P11712 1/20 0.43
TRPV1 Q8NER1 1/20 0.41
MAPK1 P28482 1/20 0.40
BLM P54132 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2911452 0.93 ALDH1A1 (0.52) ALDH1A1NPC1RAB9AMAPTHTT
SCHEMBL2909189 0.85 ALDH1A1 (0.50) ALDH1A1NPC1RAB9AMAPTHTT
SCHEMBL13175950 0.84 ALDH1A1 (0.54) ALDH1A1NPC1RAB9AMAPTHTT
SCHEMBL2942290 0.82 NPC1 (0.43) ALDH1A1NPC1RAB9AMAPTHTT
SCHEMBL2918332 0.81 ALDH1A1 (0.51) ALDH1A1NPC1RAB9AMAPTHTT
SCHEMBL2909185 0.79 ALDH1A1 (0.48) ALDH1A1NPC1RAB9AMAPTHTT
SCHEMBL2918385 0.78 ALDH1A1 (0.50) ALDH1A1NPC1RAB9AMAPTHTT
SCHEMBL13175915 0.78 ALDH1A1 (0.52) ALDH1A1NPC1RAB9AMAPTHTT
Hydrochloric Acid SCHEMBL2910578 0.78 ALDH1A1 (0.49) ALDH1A1NPC1RAB9AMAPTHTT
SCHEMBL13175624 0.76 ALDH1A1 (0.54) ALDH1A1NPC1RAB9AMAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1709047-B1 AZABENZOFURAN SUBSTITUTED THIOUREAS AS INHIBITORS OF VIRAL REPLICATION ACHILLION PHARMACEUTICALS INC (US) 2010-09-01 EP claimed
US-7439374-B2 Azabenzofuran substituted thioureas; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. (US) 2008-10-21 US claimed
US-20050228013-A1 Azabenzofuran substituted thioureas; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. 2005-10-13 US claimed
EP-1709047-B1 AZABENZOFURAN SUBSTITUTED THIOUREAS AS INHIBITORS OF VIRAL REPLICATION ACHILLION PHARMACEUTICALS INC (US) 2010-09-01 EP disclosed
US-7439374-B2 Azabenzofuran substituted thioureas; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. (US) 2008-10-21 US disclosed
US-20050228013-A1 Azabenzofuran substituted thioureas; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. 2005-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050228013-A1 Azabenzofuran substituted thioureas; inhibitors of viral replication NAT1, PIGS, ADORA1 ALDH1A1 171/4885NPC1 491/4885RAB9A 1975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.